La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Ono Pharmaceutical Salute del bilancio

Salute finanziaria criteri di controllo 5/6

Ono Pharmaceutical ha un patrimonio netto totale di ¥816.4B e un debito totale di ¥150.0B, che porta il suo rapporto debito/patrimonio netto a 18.4%. Le sue attività totali e le sue passività totali sono rispettivamente ¥1,083.7B e ¥267.3B. L'EBIT di Ono Pharmaceutical è ¥149.6B rendendo il suo rapporto di copertura degli interessi -29.7. Ha liquidità e investimenti a breve termine pari a ¥150.9B.

Informazioni chiave

18.4%

Rapporto debito/patrimonio netto

JP¥150.00b

Debito

Indice di copertura degli interessi	-29.7x
Contanti	JP¥150.92b
Patrimonio netto	JP¥816.41b
Totale passività	JP¥267.28b
Totale attività	JP¥1.08t

Aggiornamenti recenti sulla salute finanziaria

Nessun aggiornamento

Recent updates

Ono Pharmaceutical Co., Ltd. (TSE:4528) First-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year

Aug 04

There's No Escaping Ono Pharmaceutical Co., Ltd.'s (TSE:4528) Muted Earnings

Jun 24

Ono Pharmaceutical (TSE:4528) Has Announced A Dividend Of ¥40.00

Mar 04

Is There An Opportunity With Ono Pharmaceutical Co., Ltd.'s (TSE:4528) 42% Undervaluation?

Feb 27

Analisi della posizione finanziaria

Passività a breve termine: Le attività a breve termine ( ¥387.3B ) di 4528 superano le sue passività a breve termine ( ¥252.7B ).

Passività a lungo termine: Le attività a breve termine di 4528 ( ¥387.3B ) superano le sue passività a lungo termine ( ¥14.5B ).

Storia e analisi del rapporto debito/patrimonio netto

Livello di debito: 4528 ha più liquidità del suo debito totale.

Riduzione del debito: Il rapporto debito/patrimonio netto di 4528 è aumentato da 0% a 18.4% negli ultimi 5 anni.

Copertura del debito: Il debito di 4528 è ben coperto dal flusso di cassa operativo ( 80.7% ).

Copertura degli interessi: 4528 matura più interessi di quanti ne paga, quindi la copertura dei pagamenti degli interessi non è un problema.

Ono Pharmaceutical Salute del bilancio

Salute finanziaria criteri di controllo 5/6

Informazioni chiave

Aggiornamenti recenti sulla salute finanziaria

Recent updates

Ono Pharmaceutical Co., Ltd. Announces U.S. Food and Drug Administration Accepts for Priority Review Deciphera’s New Drug Application for Vimseltinib for the Treatment of Patients with Tenosynovial Giant Cell Tumor (TGCT)

Ono Pharmaceutical Co., Ltd. (TSE:4528) First-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year

First quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behind

European Medicines Agency Accepts Deciphera's Marketing Authorization Application for Vimseltinib for Treatment of Patients with Tenosynovial Giant Cell Tumor (TGCT)

Final dividend of JP¥40.00 announced

Consensus EPS estimates fall by 23%

Full year 2024 earnings: EPS and revenues miss analyst expectations

Less than half of directors are independent

There's No Escaping Ono Pharmaceutical Co., Ltd.'s (TSE:4528) Muted Earnings

Price target decreased by 10% to JP¥2,336

Ono Pharmaceutical Co., Ltd. to Report Q1, 2025 Results on Jul 31, 2024

Ono Pharmaceutical Co., Ltd. (TSE:4528) completed the acquisition of Deciphera Pharmaceuticals, Inc. (NasdaqGS:DCPH) from BlackRock, Inc. (NYSE:BLK), Deerfield Capital, L.P., Redmile Group, LLC Brightstar Associates, LLC and others.

Consensus EPS estimates fall by 11%

Consensus EPS estimates fall by 10%

Full year 2024 earnings: EPS and revenues miss analyst expectations

Ono Pharmaceutical Co., Ltd., Annual General Meeting, Jun 20, 2024

Ono Pharmaceutical Co., Ltd. (TSE:4528) entered into a definitive merger agreement to acquire Deciphera Pharmaceuticals, Inc. (NasdaqGS:DCPH) for $2.2 billion.

Ono Pharmaceutical Co., Ltd. to Report Fiscal Year 2024 Results on May 09, 2024

ONO Pharmaceuticals, Co., Ltd. Announces Enrollment is Complete for the First Arm of the PROSPECT Study of Tirabrutinib in U.S. Patients with Relapsed or Refractory PCNSL

Upcoming dividend of JP¥40.00 per share

Ono Pharmaceutical (TSE:4528) Has Announced A Dividend Of ¥40.00

Is There An Opportunity With Ono Pharmaceutical Co., Ltd.'s (TSE:4528) 42% Undervaluation?

Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Ono Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Jan 31, 2024

Price target increased by 7.4% to JP¥2,935

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Upcoming dividend of JP¥40.00 per share at 2.8% yield

Ono Pharmaceutical Co., Ltd. to Report Q2, 2024 Results on Nov 01, 2023

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Ono Pharmaceutical Co., Ltd. (TSE:4528) announces an Equity Buyback for 19,000,000 shares, representing 3.89% for ¥50,000 million.

Now 20% undervalued after recent price drop

Ono Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on Jul 31, 2023

Now 21% undervalued after recent price drop

Ono Pharmaceutical Co., Ltd., Annual General Meeting, Jun 22, 2023

Full year 2023 earnings: EPS misses analyst expectations

Upcoming dividend of JP¥33.00 per share at 2.4% yield

Price target decreased by 7.4% to JP¥3,292

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Ono Pharmaceutical Co., Ltd. (TSE:4528) acquired Research assets related to multiple research-stage oncology programs from KSQ Therapeutics, Inc.

Ono Pharmaceutical Co., Ltd. to Report Q3, 2023 Results on Jan 31, 2023

Less than half of directors are independent

Second quarter 2023 earnings: EPS exceeds analyst expectations

Upcoming dividend of JP¥33.00 per share

Ono Pharmaceutical Co., Ltd. to Report Q2, 2023 Results on Oct 31, 2022

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Now 21% undervalued

Ono Pharmaceutical Co., Ltd. to Report Q1, 2023 Results on Aug 01, 2022

Full year 2022 earnings: EPS misses analyst expectations

Ono Pharmaceutical Co., Ltd., Annual General Meeting, Jun 23, 2022

Consensus EPS estimates fall by 11%

Now 21% undervalued

Less than half of directors are independent

Ono Pharmaceutical Co., Ltd. to Report Fiscal Year 2022 Results on May 11, 2022

Upcoming dividend of JP¥28.00 per share

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Ono Pharmaceutical Co., Ltd. (TSE:4528) announces an Equity Buyback for 11,000,000 shares, representing 2.2% for ¥30,000 million.

Second quarter 2022 earnings released: EPS JP¥44.51 (vs JP¥36.77 in 2Q 2021)

Upcoming dividend of JP¥28.00 per share

Exelixis, Inc. Announces Partner Takeda Pharmaceutical Company Limited and Ono Receive Approval in Japan for CABOMETYX in Combination with Opdivo for the Treatment of Unresectable or Metastatic Renal Cell Carcinoma

First quarter 2022 earnings released: EPS JP¥48.23 (vs JP¥43.07 in 1Q 2021)

Full year 2021 earnings released: EPS JP¥151 (vs JP¥118 in FY 2020)

Full year 2021 earnings released: EPS JP¥151 (vs JP¥118 in FY 2020)

Upcoming dividend of JP¥22.50 per share

Ono Pharmaceutical Co., Ltd. to Report Fiscal Year 2021 Results on May 11, 2021

New 90-day low: JP¥3,020

Third quarter 2021 earnings released: EPS JP¥53.37 (vs JP¥38.09 in 3Q 2020)

Revenue and earnings beat expectations

ONO Receives a Manufacturing and Marketing Approval of Adlumiz (Anamorelin), a Ghrelin Receptor Agonist for the Treatment of Cancer Cachexia in Japan

Ono Pharmaceutical Co., Ltd. to Report Q3, 2021 Results on Feb 01, 2021

Ono Pharmaceutical Co., Ltd. to Report Q2, 2021 Results on Oct 29, 2020

Analisi della posizione finanziaria

Storia e analisi del rapporto debito/patrimonio netto

Bilancio

Scoprire le aziende sane